PE20160040A1 - Nuevos compuestos inhibidores de la fosfodiesterasa del tipo 10a - Google Patents
Nuevos compuestos inhibidores de la fosfodiesterasa del tipo 10aInfo
- Publication number
- PE20160040A1 PE20160040A1 PE2015001893A PE2015001893A PE20160040A1 PE 20160040 A1 PE20160040 A1 PE 20160040A1 PE 2015001893 A PE2015001893 A PE 2015001893A PE 2015001893 A PE2015001893 A PE 2015001893A PE 20160040 A1 PE20160040 A1 PE 20160040A1
- Authority
- PE
- Peru
- Prior art keywords
- new type
- inhibiting compounds
- phosphodiesterase inhibiting
- cyc3
- cyc1
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 3
- 102000004861 Phosphoric Diester Hydrolases Human genes 0.000 title abstract 2
- 108090001050 Phosphoric Diester Hydrolases Proteins 0.000 title abstract 2
- 230000002401 inhibitory effect Effects 0.000 title 1
- 229910052760 oxygen Inorganic materials 0.000 abstract 2
- 229910052717 sulfur Inorganic materials 0.000 abstract 2
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 1
- MQZSJAVVAPGAFD-UHFFFAOYSA-N 5-methyl-3-morpholin-4-yl-7-pyridin-4-ylthieno[2,3-d]pyridazin-4-one Chemical compound C1=2SC=C(N3CCOCC3)C=2C(=O)N(C)N=C1C1=CC=NC=C1 MQZSJAVVAPGAFD-UHFFFAOYSA-N 0.000 abstract 1
- 150000001204 N-oxides Chemical class 0.000 abstract 1
- 229910052736 halogen Inorganic materials 0.000 abstract 1
- 150000002367 halogens Chemical group 0.000 abstract 1
- 229910052739 hydrogen Inorganic materials 0.000 abstract 1
- 150000002431 hydrogen Chemical group 0.000 abstract 1
- 239000001257 hydrogen Substances 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Child & Adolescent Psychology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Epidemiology (AREA)
Abstract
Compuestos de la formula I, los N-oxidos, tautomeros, y las sales farmaceuticamente aceptables de los mismos; que son inhibidores de la fosfodiesterasa tipo 10. Donde Q es O o S; X1 es N o CH; X2 es O o S; R1 es Y1-Cyc1; R2 es hidrogeno, halogeno, etc.; R3 es Y3-Cyc3, R4 es C1-C4 alquilo, etc.; Y1 , Y3 es enlace, CH2, etc.; Cyc1; Cyc3 son fenilo, etc. Compuestos preferidos son: 5-metil-3-(oxetan-3-ilamino)-7-(piridin-4-il)tieno[2,3-d]piridazin-4(5H)-ona; 5-metil-3-(morfolin-4-il)-7-(piridin-4-il)tieno[2,3-d]piridazin-4(5H)-ona
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361779141P | 2013-03-13 | 2013-03-13 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20160040A1 true PE20160040A1 (es) | 2016-02-11 |
Family
ID=50241454
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2015001893A PE20160040A1 (es) | 2013-03-13 | 2014-03-12 | Nuevos compuestos inhibidores de la fosfodiesterasa del tipo 10a |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US9200005B2 (es) |
| EP (1) | EP2970328B1 (es) |
| JP (1) | JP2016510786A (es) |
| KR (1) | KR20150127724A (es) |
| CN (1) | CN105358561A (es) |
| AR (1) | AR095267A1 (es) |
| AU (1) | AU2014230825A1 (es) |
| BR (1) | BR112015022094A2 (es) |
| CA (1) | CA2902654A1 (es) |
| CL (1) | CL2015002545A1 (es) |
| CR (1) | CR20150496A (es) |
| DO (1) | DOP2015000214A (es) |
| HK (1) | HK1219273A1 (es) |
| IL (1) | IL240593A0 (es) |
| MX (1) | MX2015012389A (es) |
| PE (1) | PE20160040A1 (es) |
| PH (1) | PH12015501962A1 (es) |
| RU (1) | RU2015143536A (es) |
| SG (1) | SG11201507380PA (es) |
| TW (1) | TW201441230A (es) |
| UY (1) | UY35393A (es) |
| WO (1) | WO2014140086A1 (es) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112500338A (zh) | 2013-03-15 | 2021-03-16 | 全球血液疗法股份有限公司 | 化合物及其用于调节血红蛋白的用途 |
| EA202092627A1 (ru) | 2013-11-18 | 2021-09-30 | Глобал Блад Терапьютикс, Инк. | Соединения и их применения для модуляции гемоглобина |
| CN107074824B (zh) * | 2014-09-05 | 2021-01-08 | 基因泰克公司 | 作为用于治疗癌症的pcaf和gcn5抑制剂的式(i)的酞嗪衍生物 |
| JP6814730B2 (ja) | 2014-09-05 | 2021-01-20 | ジェネンテック， インコーポレイテッド | 治療用化合物およびその使用 |
| EP3242874B1 (en) | 2015-01-09 | 2018-10-31 | Genentech, Inc. | Pyridazinone derivatives and their use in the treatment of cancer |
| MX2019015578A (es) * | 2017-06-28 | 2020-07-28 | Ptc Therapeutics Inc | Metodos para tratar la enfermedad de huntington. |
| GB202106872D0 (en) * | 2021-05-13 | 2021-06-30 | Addex Pharmaceuticals Sa | Novel compounds |
| CN115838364A (zh) * | 2022-12-20 | 2023-03-24 | 河南沁朋科技有限公司 | 一种3,3-双噻吩的合成方法 |
| TW202506660A (zh) * | 2023-04-27 | 2025-02-16 | 美商塞普特納公司 | Mrgprx2拮抗劑及其使用方法 |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1999029695A1 (en) | 1997-12-05 | 1999-06-17 | Astrazeneca Uk Limited | Novel compounds |
| US20030032579A1 (en) | 2001-04-20 | 2003-02-13 | Pfizer Inc. | Therapeutic use of selective PDE10 inhibitors |
| SE0300120D0 (sv) * | 2003-01-17 | 2003-01-17 | Astrazeneca Ab | Novel compounds |
| WO2005012485A2 (en) | 2003-07-31 | 2005-02-10 | Bayer Pharmaceuticals Corporation | Methods for treating diabetes and related disorders using pde10a inhibitors |
| EP1755611A1 (en) | 2004-06-07 | 2007-02-28 | Pfizer Products Inc. | Phosphodiesterase 10 inhibition as treatment for obesity-related and metabolic syndrome-related conditions |
| JP2008512375A (ja) | 2004-09-03 | 2008-04-24 | メモリ ファーマセチカル コーポレーション | 精神医学的又は神経学的症候群の治療用のホスホジエステラーゼ１０阻害剤としての４−置換４，６−ジアルコキシ−シンノリン誘導体 |
| AU2006279548A1 (en) | 2005-08-16 | 2007-02-22 | Amgen, Inc. | Phosphodiesterase 10 inhibitors |
| NL2000397C2 (nl) | 2006-01-05 | 2007-10-30 | Pfizer Prod Inc | Bicyclische heteroarylverbindingen als PDE10 inhibitoren. |
| WO2007082546A1 (en) | 2006-01-20 | 2007-07-26 | H. Lundbeck A/S | Use of tofisopam as a pde10a inhibitor |
| CA2635439A1 (en) | 2006-01-27 | 2007-08-02 | Pfizer Products Inc. | Aminophthalazine derivative compounds |
| US20070265270A1 (en) | 2006-02-21 | 2007-11-15 | Hitchcock Stephen A | Cinnoline derivatives as phosphodiesterase 10 inhibitors |
| AU2007217750A1 (en) | 2006-02-21 | 2007-08-30 | Amgen Inc. | Cinnoline derivatives as phosphodiesterase 10 inhibitors |
| JP2009527542A (ja) | 2006-02-23 | 2009-07-30 | ファイザー・プロダクツ・インク | Ｐｄｅ１０阻害薬としての置換キナゾリン |
| US20070287707A1 (en) | 2006-02-28 | 2007-12-13 | Arrington Mark P | Phosphodiesterase 10 inhibitors |
| US20070265258A1 (en) | 2006-03-06 | 2007-11-15 | Ruiping Liu | Quinazoline derivatives as phosphodiesterase 10 inhibitors |
| JP2009529060A (ja) | 2006-03-08 | 2009-08-13 | アムゲン インコーポレイティッド | ホスホジエステラーゼ１０阻害剤としてのキノリン及びイソキノリン誘導体 |
| TW200817400A (en) | 2006-05-30 | 2008-04-16 | Elbion Ag | Pyrido [3,2-e] pyrazines, their use as inhibitors of phosphodiesterase 10, and processes for preparing them |
| TW200815436A (en) | 2006-05-30 | 2008-04-01 | Elbion Ag | 4-amino-pyrido[3,2-e]pyrazines, their use as inhibitors of phosphodiesterase 10, and processes for preparing them |
| CA2654394A1 (en) | 2006-06-26 | 2008-01-03 | Pfizer Products Inc. | Tricyclic heteroaryl compounds as pde10 inhibitors |
| US20080090834A1 (en) | 2006-07-06 | 2008-04-17 | Pfizer Inc | Selective azole pde10a inhibitor compounds |
| HRP20120835T1 (hr) | 2006-07-10 | 2012-11-30 | H. Lundbeck A/S | (3-aril-piperazin-1-il) derivati 6,7-dialkoksikinazolina, 6,7-dialkoksiftalazina i 6,7-dialkoksiizokinolina |
| WO2008020302A2 (en) | 2006-08-17 | 2008-02-21 | Pfizer Products Inc. | Heteroaromatic quinoline-based compounds as phosphodiesterase (pde) inhibitors |
| WO2009025823A1 (en) | 2007-08-21 | 2009-02-26 | Amgen Inc. | Phosphodiesterase 10 inhibitors |
| WO2009025839A2 (en) | 2007-08-22 | 2009-02-26 | Amgen Inc. | Phosphodiesterase 10 inhibitors |
| US20090054434A1 (en) | 2007-08-23 | 2009-02-26 | Amgen Inc. | Isoquinolone derivatives as phosphodiesterase 10 inhibitors |
| TW200918519A (en) | 2007-09-19 | 2009-05-01 | Lundbeck & Co As H | Cyanoisoquinoline |
| US20090143361A1 (en) | 2007-11-30 | 2009-06-04 | Elbion Gmbh | Pyrido[3,2-E]Pyrazines, Process For Preparing The Same, And Their Use As Inhibitors Of Phosphodiesterase 10 |
| US7875618B2 (en) | 2007-11-30 | 2011-01-25 | Wyeth | Substituted imidazo[1,5-a]quinoxalines useful as inhibitors of phosphodiesterase 10 for the treatment of neurological and other disorders |
| AU2008329072A1 (en) | 2007-11-30 | 2009-06-04 | Elbion Gmbh | Aryl and heteroaryl fused imidazo (1,5-A) pyrazines as inhibitors of phosphodiesterase 10 |
| US20090143392A1 (en) | 2007-11-30 | 2009-06-04 | Elbion Gmbh | Methods of Treating Obesity and Metabolic Disorders |
| US8389567B2 (en) * | 2007-12-12 | 2013-03-05 | Calcimedica, Inc. | Compounds that modulate intracellular calcium |
| EP2471791B1 (en) * | 2009-08-26 | 2014-11-12 | Takeda Pharmaceutical Company Limited | Fused heterocyclic ring derivative and use thereof |
| US20130203756A1 (en) | 2010-10-29 | 2013-08-08 | Jamie L. Bunda | Isoindoline pde10 inhibitors |
| US9938269B2 (en) | 2011-06-30 | 2018-04-10 | Abbvie Inc. | Inhibitor compounds of phosphodiesterase type 10A |
| US20130116241A1 (en) | 2011-11-09 | 2013-05-09 | Abbvie Inc. | Novel inhibitor compounds of phosphodiesterase type 10a |
-
2014
- 2014-02-25 US US14/189,961 patent/US9200005B2/en not_active Expired - Fee Related
- 2014-03-12 RU RU2015143536A patent/RU2015143536A/ru unknown
- 2014-03-12 KR KR1020157029132A patent/KR20150127724A/ko not_active Withdrawn
- 2014-03-12 WO PCT/EP2014/054810 patent/WO2014140086A1/en not_active Ceased
- 2014-03-12 BR BR112015022094A patent/BR112015022094A2/pt not_active IP Right Cessation
- 2014-03-12 HK HK16107260.0A patent/HK1219273A1/zh unknown
- 2014-03-12 JP JP2015562117A patent/JP2016510786A/ja active Pending
- 2014-03-12 EP EP14709320.7A patent/EP2970328B1/en not_active Not-in-force
- 2014-03-12 AU AU2014230825A patent/AU2014230825A1/en not_active Abandoned
- 2014-03-12 TW TW103108560A patent/TW201441230A/zh unknown
- 2014-03-12 CA CA2902654A patent/CA2902654A1/en not_active Abandoned
- 2014-03-12 CN CN201480014146.XA patent/CN105358561A/zh active Pending
- 2014-03-12 PE PE2015001893A patent/PE20160040A1/es not_active Application Discontinuation
- 2014-03-12 MX MX2015012389A patent/MX2015012389A/es unknown
- 2014-03-12 SG SG11201507380PA patent/SG11201507380PA/en unknown
- 2014-03-12 UY UY0001035393A patent/UY35393A/es not_active Application Discontinuation
- 2014-03-12 AR ARP140100879A patent/AR095267A1/es unknown
-
2015
- 2015-08-16 IL IL240593A patent/IL240593A0/en unknown
- 2015-09-03 DO DO2015000214A patent/DOP2015000214A/es unknown
- 2015-09-04 PH PH12015501962A patent/PH12015501962A1/en unknown
- 2015-09-09 CL CL2015002545A patent/CL2015002545A1/es unknown
- 2015-09-16 CR CR20150496A patent/CR20150496A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| TW201441230A (zh) | 2014-11-01 |
| JP2016510786A (ja) | 2016-04-11 |
| EP2970328B1 (en) | 2017-04-26 |
| CL2015002545A1 (es) | 2016-07-22 |
| SG11201507380PA (en) | 2015-10-29 |
| CA2902654A1 (en) | 2014-09-18 |
| MX2015012389A (es) | 2016-03-03 |
| HK1219273A1 (zh) | 2017-03-31 |
| AU2014230825A1 (en) | 2015-09-03 |
| CN105358561A (zh) | 2016-02-24 |
| IL240593A0 (en) | 2015-09-24 |
| RU2015143536A (ru) | 2017-04-18 |
| PH12015501962A1 (en) | 2016-01-11 |
| KR20150127724A (ko) | 2015-11-17 |
| US20140275069A1 (en) | 2014-09-18 |
| DOP2015000214A (es) | 2015-12-31 |
| EP2970328A1 (en) | 2016-01-20 |
| BR112015022094A2 (pt) | 2018-06-12 |
| US9200005B2 (en) | 2015-12-01 |
| WO2014140086A1 (en) | 2014-09-18 |
| CR20150496A (es) | 2016-02-19 |
| UY35393A (es) | 2014-10-31 |
| AR095267A1 (es) | 2015-09-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20160040A1 (es) | Nuevos compuestos inhibidores de la fosfodiesterasa del tipo 10a | |
| EP4247369A4 (en) | SPIROCYCLIC-SUBSTITUTED 6,7-DIHYDRO-PYRANO[2,3-D]PYRIMIDINE INHIBITORS OF THE KRAS G12C MUTANT | |
| NZ629025A (en) | Naphthyridine derivatives useful as alpha-v-beta-6 integrin antagonists | |
| PH12017502171A1 (en) | PYRIDO[3,4-d]PYRIMIDINE DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | |
| PE20191245A1 (es) | Compuestos de tiazolcarboxamidas y piridinacarboxamida utiles como inhibidores de quinasa pim | |
| MY204050A (en) | Benzolactam compounds as protein kinase inhibitors | |
| NZ626394A (en) | Substituted annulated pyrimidines and triazines, and use thereof | |
| PE20200388A1 (es) | Amidas heterociclicas de 5 miembros y biciclicas como inhibidores de rock | |
| EA201400182A1 (ru) | Производные пиридин-2(1н)-она в качестве ингибиторов jak | |
| PE20161246A1 (es) | Acrilamidas de pirrolo[2,3-d]pirimidinilo, pirrolo[2,3-b]pirazinilo y pirrolo[2,3-d]piridinilo | |
| TN2013000394A1 (fr) | Derives de pyrrolo [2,3-d] pyrimidine servant d'inhibiteurs de kinases apparentees a la tropomyosine | |
| NZ599040A (en) | 2,4-disubstituted pyrido[4,3-d]pyrimidin-5(6h)-one compounds for selective inhibitors of lrrk2 and syk kinases | |
| PE20190339A1 (es) | 1h-pirazolo[4,3-b] piridinas como inhibidores de pde1 | |
| NI201200192A (es) | Derivados de imidazopiridina, su procedimiento de preparación y su aplicación en terapéutica. | |
| AR091285A1 (es) | Inhibidores de bromodominio y sus usos | |
| GEP20197050B (en) | Solid state forms of fused heteroaromatic pyrrolidinones | |
| JO3261B1 (ar) | مشتق بيريدين أحادي الحلقة | |
| ECSP109964A (es) | Pirimidinas bicíclicas fusionadas | |
| PE20141553A1 (es) | Compuestos de triazolopiridina como inhibidores de la ped10a | |
| BR112015032132A2 (pt) | cristais de base livre | |
| PE20170640A1 (es) | Derivados de quinolizinona como inhibidores de pi3k | |
| MY169128A (en) | Pd-catalyzed coupling of pyrazole amides | |
| PE20170009A1 (es) | Compuestos heteroaromaticos y su uso como ligandos de dopamina d1 | |
| PE20151940A1 (es) | Derivados de triazina | |
| EA201590069A1 (ru) | Пиримидиноновые производные в качестве антималярийных средств |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FD | Application declared void or lapsed |